| Literature DB >> 27231692 |
Gopi Mara-Koosham1, Karl Stoltze1, Jeffrey Aday1, Patrick Rendon1.
Abstract
Pulmonary renal syndrome is a class of small vessel vasculitides that are characterized by the dual presentation of diffuse alveolar hemorrhage (DAH) and glomerulonephritis. Pulmonary renal syndrome has multiple etiologies, but its development has been rarely reported following infection with group A streptococcus. We present the case of a 36-year-old Native American male who was transferred to our facility due to refractory hypoxic respiratory failure. He had been diagnosed with streptococcal pharyngitis 2 weeks prior to admission. Given the presence of hemoptysis, bronchoscopy was performed and was consistent with DAH. Urinalysis demonstrated hematuria and proteinuria, in the setting of elevated creatinine and blood urea nitrogen. Additionally, antistreptolysin O titer was positive. Given the constellation of laboratory findings and history of streptococcal pharyngitis, the patient was diagnosed with PRS secondary to streptococcal infection. High-dose methylprednisolone was initiated with concomitant plasmapheresis. He was extubated successfully after his respiratory status improved and was eventually discharged home after making a full recovery within 2 weeks after admission. This case illustrates the importance of clinically relevant sequelae of streptococcal infection as well as the appropriate treatment of PRS secondary to streptococcal pharyngitis with plasmapheresis and intravenous corticosteroids.Entities:
Keywords: diffuse alveolar hemorrhage; plasmapheresis; post-streptococcal glomerulonephritis; pulmonary renal syndrome
Year: 2016 PMID: 27231692 PMCID: PMC4871206 DOI: 10.1177/2324709616646127
Source DB: PubMed Journal: J Investig Med High Impact Case Rep ISSN: 2324-7096
Laboratory Findings of the Patient on the Day of Admission.
| CBC with differential | WBC 20.8; RBC 4.35; platelets 380; Hgb 12.8; HCT 39; MCV 90; MCHC 32.6; RDWC 14.2; protime 14.6 seconds; INR 1.16; total bilirubin 0.8 (direct 0.3; indirect 0.5) |
| CRP | 11.5 mg/dL |
| Albumin | 2.5 g/dL |
| Toxicology screen | Negative for amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, opioids, ethanol |
| Arterial blood gas | pH 7.29; pCO2 43 mm Hg; pO2 58 mm Hg; HCO3− 20 mEq/L |
| Rheumatology panel | Negative for rheumatoid factor, anti-DNA, anti-neutrophil cytoplasm, anti-proteinase-3, anti-myeloperoxidase, anti-Smith Abs, anti-RNP, SS-A, SS-B, anti-GBM, cyclic citrullinated peptide |
| C3 | 9 mg/dL |
| C4 | 8.9 mg/dL |
| ASO | 1270 IU/mL |
| Fibrinogen | 566 mg/dL |
| Urine analysis | Cloudy, specific gravity 1.046; RBC >150/HPF; WBC 25/HPF; protein 100 mg/dL |
Abbreviations: WBC, white blood cell; RBC, red blood cell; Hgb, hemoglobin; HCT, hematocrit; MCV, Mean corpuscular volume; MCHC, mean corpuscular hemoglobin concentration; RDWC, red blood cell distribution width; INR, international normalized ratio; CRP, C-reactive protein; ASO, anti-streptolysin O; HPF, high-power field.
Figure 1.AP view of patient’s chest radiograph showing bilateral airspace consolidation and cardiomegaly suggestive of pulmonary edema.
Figure 2.Plasmapheresis and high-dose corticosteroid treatment improved the patient’s renal function. Patient was started on daily intravenous methylprednisolone treatment (1 g/day) and subjected to plasmapheresis on days 2, 3, 5, and 7 postadmission (indicated by arrows). Creatinine and blood urea nitrogen were measured daily.
Figure 3.Plasmapheresis and high-dose corticosteroid treatment decreased the ASO titers while increasing the C3 and C4 levels. Patient was started on daily intravenous methylprednisolone treatment (1 g/day) and subjected to plasmapheresis on days 2, 3, 5, and 7 postadmission. Antistreptolysin O titers and C3 and C4 levels were measured on the indicated days.